Eli Lilly and Company with ticker code (LLY) have now 27 analysts in total covering the stock. The consensus rating is pointing to ‘buy’. The target price High/Low ranges between $1,250.00 and $580.00 suggesting an average analyst share price target price of $984.05. (at the time of writing). Given that the stocks previous close was at $765.10 this now indicates there is a potential upside of 28.6%. Also worth taking note is the 50 day moving average now sits at $795.27 and the 200 moving average now moves to $839.50. The company has a market capitalization of 695.43B. The stock price is currently at: $773.29 USD
The potential market cap would be $894,440,991,914 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 83.33, revenue per share of $45.37 and a 13.95% return on assets.
Eli Lilly and Company is engaged in drug manufacturing businesses. The Company discovers, develops, manufactures, and markets products in the human pharmaceutical products segment. Its diabetes products include Basaglar, Humalog, Humulin, Jardiance, Mounjaro, and Trulicity. Its oncology products consist of Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. Its immunology products include Olumiant and Taltz. Its neuroscience products include Cymbalta, Emgality, and Zyprexa. Its other therapies consist of Bamlanivimab and etesevimab, Bebtelovimab, Cialis, and Forteo. It maintains special business groups for service wholesalers, pharmacy benefit managers, managed care organizations, group purchasing organizations, government and long-term care institutions, hospitals, and certain retail pharmacies. It manufactures and distributes its products through facilities in the United States, including Puerto Rico, and other countries. Its products are sold in over 110 countries.
